Headache

Calcitonin Gene-Related Peptide Antibody Therapy for Migraine

Cleveland Clinic’s Section of Headache and Facial Pain, within the Center for Neurological Restoration, is among the largest and most comprehensive centers in the world dedicated to managing and treating headache and facial pain syndrome.

Outcomes Following Treatment With CGRP Monoclonal Antibodies (N = 205)

2023

CGRP = Calcitonin Gene-Related Peptide, GAD-7 = Generalized Anxiety Disorder Questionnaire, HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System.

The Cleveland Clinic Headache Center has been prescribing one of the most innovative treatments, calcitonin gene-related peptide (CGRP) targeting therapy, for migraine patients. In 2023, 205 headache patients were prescribed this treatment and completed at least 1 follow-up questionnaire. Ninety percent of patients had improved or stable headache impact scores.¹ PROMIS global health,² depression,³ and anxiety⁴ were stable or improved in 88% of patients or more.

References
  1. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006 Apr;59(4):374-380.
  2. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009 Sep;18(7):873-880.
  3. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004 Dec;42(12):1194-1201.
  4. Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Harter M, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401.